MedTrace Logo

Use of the VisuMax™ Femtosecond Laser

NCT01638390 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2026-04-02

Study results available
· View outcomes & findings →

Summary

The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.

Conditions

  • Myopia

Interventions

DEVICE

Treatment with the VisuMax™ Femtosecond Laser

The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.

Sponsors & Collaborators

  • Carl Zeiss Meditec, Inc.

    lead INDUSTRY

Principal Investigators

  • Jon Dishler, M.D. · Dishler Laser Institute

  • John Doane, M.D. · Discover Vision Centers

  • Vance Thompson, M.D. · Vance Thompson Vision Clinic, Prof., LLC

  • William Culbertson, M.D. · Bascom Palmer Eye Institute

  • Sonia Yoo, M.D. · Bascom Palmer Eye Institute

  • John Vukich, M.D. · Davis Duehr Dean

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638390 on ClinicalTrials.gov